Goldberg RA, Hill LF, Davis T, et al. - Researchers conducted the study for determining the potential effect on visual outcomes of delayed treatment initiation in patients with neovascular age-related macular degeneration (nAMD). It was a post hoc analysis of anti-vascular endothelial growth factor treatment-naïve patients with nAMD from HARBOR. They defined the time to treatment as the first ranibizumab injection date minus screening date. In HARBOR, more than 50% of participants took their first injection within 7 days of screening, with a mean (median) time to treatment of 4.6 (5) and 15.9 (14) days for the prompt and delayed treatment groups, respectively. In HARBOR, time from screening to first ranibizumab injection did not appear to significantly influence mean BCVA change or the number of injections.